Kidney Cancer Clinical Trial

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Summary

The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.

View Full Description

Full Description

The primary objectives of the study are a) to allow patients from Bayer-sponsored trials to continue regorafenib treatment after their respective study has been completed, and b) to further assess the safety of regorafenib. Secondary objective is the documentation of drug tolerability.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant must be age-eligible in the feeder study at the time of signing the informed consent.
Participant is currently participating in any Bayer-sponsored regorafenib study and is receiving study treatment.
Participant is currently benefiting from treatment with regorafenib monotherapy and meets criteria to initiate a subsequent cycle of therapy, as determined by the guidelines of the feeder protocol.
Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator.

Exclusion Criteria:

Medical reasons not to start the next treatment cycle in the respective feeder
Pregnancy

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

6

Study ID:

NCT03890731

Recruitment Status:

Completed

Sponsor:

Bayer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Tampa General Medical Group
Tampa Florida, 33606, United States
Eberhard-Karls-Universität Tübingen
Tübingen Baden-Württemberg, 72076, Germany
Universitätsklinikum Köln
Köln Nordrhein-Westfalen, 50937, Germany
A.O.U. Careggi
Firenze Toscana, 50134, Italy
Saiseikai Utsunomiya Hospital
Utsunomiya-shi Tochigi, 321-0, Japan
Mount Vernon Hospital
Northwood , HA6 2, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

6

Study ID:

NCT03890731

Recruitment Status:

Completed

Sponsor:


Bayer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.